{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:49:50Z","timestamp":1733896190986,"version":"3.30.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00108-024-01792-2","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:02:35Z","timestamp":1727434955000},"page":"1180-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der Therapie der komplizierten Harnwegsinfektionen","What is confirmed in therapy of complicated urinary tract infections"],"prefix":"10.1007","volume":"65","author":[{"given":"Sibylle","family":"von Vietinghoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.15971020","volume":"17","author":"A Agrawal","year":"2022","unstructured":"Agrawal\u00a0A, Ison\u00a0MG, Danziger-Isakov\u00a0L (2022) Long-Term Infectious Complications of Kidney Transplantation. Clin J Am Soc Nephrol 17:286\u2013295. https:\/\/doi.org\/10.2215\/CJN.15971020","journal-title":"Clin J Am Soc Nephrol"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jama.2021.9899","volume":"326","author":"DM Drekonja","year":"2021","unstructured":"Drekonja\u00a0DM, Trautner\u00a0B, Amundson\u00a0C et\u00a0al (2021) Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A\u00a0Randomized Clinical Trial. JAMA 326:324\u2013331. https:\/\/doi.org\/10.1001\/jama.2021.9899","journal-title":"JAMA"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg\u00a0PB, Muir\u00a0L, Critchley\u00a0IA et\u00a0al (2022) Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N\u00a0Engl J Med 386:1327\u20131338. https:\/\/doi.org\/10.1056\/NEJMoa2105462","journal-title":"N Engl J Med"},{"key":"1792_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013788.pub2","author":"M Goodfellow","year":"2023","unstructured":"Goodfellow\u00a0M, Thompson\u00a0ER, Tingle\u00a0SJ, Wilson\u00a0C (2023) Early versus late removal of urinary catheter after kidney transplantation. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD013788.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.61409\/A06230424","volume":"71","author":"ADM Hamilton","year":"2024","unstructured":"Hamilton\u00a0ADM, Pr\u00e6torius\u00a0HA (2024) Reduced graft survival in renal transplant patients with urinary tract infections\u2014a\u00a0meta-analysis. Dan Med\u00a0J 71:1\u201312. https:\/\/doi.org\/10.61409\/A06230424","journal-title":"Dan Med J"},{"key":"1792_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijantimicag.2011.09.009","volume":"38","author":"TEB Johansen","year":"2011","unstructured":"Johansen\u00a0TEB, Botto\u00a0H, Cek\u00a0M et\u00a0al (2011) Critical review of current definitions of urinary tract infections and proposal of an EAU\/ESIU classification system. Int J Antimicrob Agents 38:64\u201370. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.09.009","journal-title":"Int J Antimicrob Agents"},{"key":"1792_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","volume":"328","author":"KS Kaye","year":"2022","unstructured":"Kaye\u00a0KS, Belley\u00a0A, Barth\u00a0P et\u00a0al (2022) Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A\u00a0Randomized Clinical Trial. JAMA 328:1304\u20131314. https:\/\/doi.org\/10.1001\/jama.2022.17034","journal-title":"JAMA"},{"key":"1792_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye\u00a0KS, Bhowmick\u00a0T, Metallidis\u00a0S et\u00a0al (2018) Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 319:788\u2013799. https:\/\/doi.org\/10.1001\/jama.2018.0438","journal-title":"JAMA"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","volume":"86","author":"J Kranz","year":"2024","unstructured":"Kranz\u00a0J, Bartoletti\u00a0R, Bruy\u00e8re\u00a0F et\u00a0al (2024) European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol 86:27\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.035","journal-title":"Eur Urol"},{"key":"1792_CR10","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0104","author":"J Kranz","year":"2022","unstructured":"Kranz\u00a0J, Lackner\u00a0J, K\u00fcnzel\u00a0U et\u00a0al (2022) Phytotherapy in adults with recurrent uncomplicated cystitis. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2022.0104","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"1792_CR11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/cid\/ciad070","volume":"76","author":"M Lafaurie","year":"2023","unstructured":"Lafaurie\u00a0M, Chevret\u00a0S, Fontaine\u00a0J\u2011P et\u00a0al (2023) Antimicrobial for 7\u00a0or 14 Days for Febrile Urinary Tract Infection in Men: A\u00a0Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clin Infect Dis 76:2154\u20132162. https:\/\/doi.org\/10.1093\/cid\/ciad070","journal-title":"Clin Infect Dis"},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","volume":"15","author":"C van Nieuwkoop","year":"2017","unstructured":"van Nieuwkoop\u00a0C, van der Starre\u00a0WE, Stalenhoef\u00a0JE et\u00a0al (2017) Treatment duration of febrile urinary tract infection: a\u00a0pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med 15:70. https:\/\/doi.org\/10.1186\/s12916-017-0835-3","journal-title":"BMC Med"},{"key":"1792_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004925.pub4","author":"LG Patterson","year":"2024","unstructured":"Patterson\u00a0LG, Tingle\u00a0SJ, Rix\u00a0DA et\u00a0al (2024) Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004925.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1792_CR14","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.3399\/BJGP.2022.0354","volume":"73","author":"TN Platteel","year":"2023","unstructured":"Platteel\u00a0TN, Beets\u00a0MT, Teeuwissen\u00a0HA et\u00a0al (2023) Nitrofurantoin failure in males with an uncomplicated urinary tract infection: a\u00a0primary care observational cohort study. Br J Gen Pract 73:e204\u2013e210. https:\/\/doi.org\/10.3399\/BJGP.2022.0354","journal-title":"Br J Gen Pract"},{"key":"1792_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth\u00a0S, van Veenhuyzen\u00a0D, Echols\u00a0R et\u00a0al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a\u00a0phase\u00a02, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328. https:\/\/doi.org\/10.1016\/S1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eclinm.2019.07.012","volume":"14","author":"M Pujades-Rodriguez","year":"2019","unstructured":"Pujades-Rodriguez\u00a0M, West\u00a0RM, Wilcox\u00a0MH, Sandoe\u00a0J (2019) Lower Urinary Tract Infections: Management, Outcomes and Risk Factors for Antibiotic Re-prescription in Primary Care. EClinicalMedicine 14:23\u201331. https:\/\/doi.org\/10.1016\/j.eclinm.2019.07.012","journal-title":"EClinicalMedicine"},{"key":"1792_CR17","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2023.0207","author":"H S\u00e6tre","year":"2024","unstructured":"S\u00e6tre\u00a0H, Skow\u00a0M, Vik\u00a0I et\u00a0al (2024) Acute cystitis in men- a\u00a0nationwide study from primary care: antibiotic prescriptions, risk factors, and complications. BJGP Open. https:\/\/doi.org\/10.3399\/BJGPO.2023.0207","journal-title":"BJGP Open"},{"key":"1792_CR18","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2024.0068","author":"G Schmiemann","year":"2024","unstructured":"Schmiemann\u00a0G, Kranz\u00a0J, Mandraka\u00a0F et\u00a0al (2024) The diagnosis, treatment, and prevention of recurrent urinary tract infection. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2024.0068","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"1792_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/antibiotics11060768","volume":"11","author":"A Silva","year":"2022","unstructured":"Silva\u00a0A, Costa\u00a0E, Freitas\u00a0A, Almeida\u00a0A (2022) Revisiting the Frequency and Antimicrobial Resistance Patterns of Bacteria Implicated in Community Urinary Tract Infections. Antibiotics 11:768. https:\/\/doi.org\/10.3390\/antibiotics11060768","journal-title":"Antibiotics"},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims\u00a0M, Mariyanovski\u00a0V, McLeroth\u00a0P et\u00a0al (2017) Prospective, randomized, double-blind, Phase\u00a02 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J\u00a0Antimicrob Chemother 72:2616\u20132626. https:\/\/doi.org\/10.1093\/jac\/dkx139","journal-title":"J Antimicrob Chemother"},{"key":"1792_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00345-024-04979-2","volume":"42","author":"Z Tandogdu","year":"2024","unstructured":"Tandogdu\u00a0Z, Koves\u00a0B, Ristovski\u00a0S et\u00a0al (2024) Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a\u00a0prospective, observational multi-center study. World J Urol 42:314. https:\/\/doi.org\/10.1007\/s00345-024-04979-2","journal-title":"World J Urol"},{"key":"1792_CR22","doi-asserted-by":"publisher","first-page":"101750","DOI":"10.1016\/j.eclinm.2022.101750","volume":"55","author":"A Turjeman","year":"2023","unstructured":"Turjeman\u00a0A, von Dach\u00a0E, Molina\u00a0J et\u00a0al (2023) Duration of antibiotic treatment for Gram-negative bacteremia\u2014Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine 55:101750. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101750","journal-title":"EClinicalMedicine"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1464-410x.1999.00164.x","volume":"84","author":"P Ulleryd","year":"1999","unstructured":"Ulleryd\u00a0P, Zackrisson\u00a0B, Aus\u00a0G et\u00a0al (1999) Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 84:470\u2013474. https:\/\/doi.org\/10.1046\/j.1464-410x.1999.00164.x","journal-title":"BJU Int"},{"key":"1792_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/ndt\/gfad233","volume":"39","author":"S Von Vietinghoff","year":"2024","unstructured":"Von Vietinghoff\u00a0S, Shevchuk\u00a0O, Dobrindt\u00a0U et\u00a0al (2024) The global burden of antimicrobial resistance\u2014urinary tract infections. Nephrol Dial Transplant 39:581\u2013588. https:\/\/doi.org\/10.1093\/ndt\/gfad233","journal-title":"Nephrol Dial Transplant"},{"key":"1792_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","volume":"403","author":"F Wagenlehner","year":"2024","unstructured":"Wagenlehner\u00a0F, Perry\u00a0CR, Hooton\u00a0TM et\u00a0al (2024) Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE\u20112 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase\u00a03, non-inferiority trials. Lancet 403:741\u2013755. https:\/\/doi.org\/10.1016\/S0140-6736(23)02196-7","journal-title":"Lancet"},{"key":"1792_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","volume":"390","author":"FM Wagenlehner","year":"2024","unstructured":"Wagenlehner\u00a0FM, Gasink\u00a0LB, McGovern\u00a0PC et\u00a0al (2024) Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N\u00a0Engl J Med 390:611\u2013622. https:\/\/doi.org\/10.1056\/NEJMoa2304748","journal-title":"N Engl J Med"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner\u00a0FM, Sobel\u00a0JD, Newell\u00a0P et\u00a0al (2016) Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a\u00a0Phase\u00a03 Randomized Trial Program. Clin Infect Dis 63:754\u2013762. https:\/\/doi.org\/10.1093\/cid\/ciw378","journal-title":"Clin Infect Dis"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner\u00a0FM, Umeh\u00a0O, Steenbergen\u00a0J et\u00a0al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase\u00a03\u00a0trial (ASPECT-cUTI). Lancet 385:1949\u20131956. https:\/\/doi.org\/10.1016\/S0140-6736(14)62220-0","journal-title":"Lancet"},{"key":"1792_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","volume":"17","author":"FME Wagenlehner","year":"2020","unstructured":"Wagenlehner\u00a0FME, Bjerklund Johansen\u00a0TE, Cai\u00a0T et\u00a0al (2020) Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol 17:586\u2013600. https:\/\/doi.org\/10.1038\/s41585-020-0362-4","journal-title":"Nat Rev Urol"},{"key":"1792_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner\u00a0FME, Cloutier\u00a0DJ, Komirenko\u00a0AS et\u00a0al (2019) Once-Daily Plazomicin for Complicated Urinary Tract Infections. N\u00a0Engl J Med 380:729\u2013740. https:\/\/doi.org\/10.1056\/NEJMoa1801467","journal-title":"N Engl J Med"},{"key":"1792_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001321.pub6","author":"G Williams","year":"2023","unstructured":"Williams\u00a0G, Hahn\u00a0D, Stephens\u00a0JH et\u00a0al (2023) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001321.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"1792_CR32","unstructured":"S3-Leitlinie Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen (HWI)."}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01792-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T22:03:06Z","timestamp":1733868186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01792-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01792-2","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"30 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0von Vietinghoff und F.\u00a0Wagenlehner geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Unsere Arbeit wird von der DFG (FOR5427 BARICADE) unterst\u00fctzt.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}